ON-DEMAND WEBINARS

Using volatile processing aids to increase drug solubility in more environmentally friendly solvents, like methanol, reduces the amount of solvent required to manufacture amorphous solid dispersions (ASDs).

Led by Dr. Richard Johnson, Chief Scientific Officer, this 40-minute session covers the five key stages of the UpperNose development platform, highlighting the significance of target product selection and its influence on formulation and clinical outcomes.

Learn how techniques and innovations in taste masking sensory and performance evaluation can help accelerate your formulation development and confirm desired taste profile.

Discover a screening process to quickly assess HME feasibility that yields more accurate predictions for API loading and degradation while saving material and time compared to traditional approaches.

ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

TVG-New

Fran DeGrazio, Executive Editor - Drug Delivery Leader & Frankly Fran

Fran offers keen industry and technical insights exclusively on Drug Delivery Leader.

DELIVERED BY DEGRAZIO

  • 4 Opportunities For Advancing Drug Delivery

    In this article, Fran DeGrazio identifies four prime opportunities for drug delivery developers to move the dial of innovation into 2026 and beyond. These avenues for advancement include diagnostics, patient tolerability, microdosing, and analytical methodologies. 

FREE EBOOK: COMBINATION PRODUCTS

Combination products provide significant avenues for increasing patient adherence and overall efficacy. This collection outlines the opportunity and identifies strategies for gaining regulatory approval.